Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial

INTRODUCTION: Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate-to-severe plaque psoriasis in a phase 2 clinical study. Herein we report the results of 54 weeks of a phase 3 PLANETA trial aimed to evaluate the efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Puig, Luís, Bakulev, Andrey L., Kokhan, Muza M., Samtsov, Alexey V., Khairutdinov, Vladislav R., Morozova, Maria A., Zolkin, Nikita A., Kuryshev, Ivan V., Petrov, Alexey N., Artemeva, Antonina V., Zinkina-Orikhan, Arina V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322379/
https://www.ncbi.nlm.nih.gov/pubmed/34060012
http://dx.doi.org/10.1007/s13555-021-00554-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322379/
https://www.ncbi.nlm.nih.gov/pubmed/34060012
http://dx.doi.org/10.1007/s13555-021-00554-4

Ejemplares similares